Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ACETAMINOPHEN AND HYDROCODONE BITARTRATE vs CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Acetaminophen: analgesic and antipyretic effects via inhibition of cyclooxygenase (COX) and activation of descending serotonergic pathways; central action. Hydrocodone: mu-opioid receptor agonist; activates G-protein coupled receptors to modulate pain perception and emotional response.
Calcipotriene is a synthetic vitamin D3 analog that binds to vitamin D receptors, regulating cell proliferation and differentiation. Betamethasone dipropionate is a corticosteroid that reduces inflammation by inducing phospholipase A2 inhibitory proteins (lipocortins), inhibiting arachidonic acid release, and decreasing prostaglandin and leukotriene synthesis.
Moderate to moderately severe pain,Cough suppression (hydrocodone; off-label)
Treatment of plaque psoriasis (FDA-approved)
1-2 tablets (containing 5-10 mg hydrocodone and 300-325 mg acetaminophen) orally every 4-6 hours as needed for pain; maximum 8 tablets per day.
Apply once daily to affected areas of skin, not exceeding 100 g/week or 30 m L/day. Do not use under occlusive dressings.
Acetaminophen: 2-3 hours in adults; prolonged in hepatic impairment (up to 5 hours). Hydrocodone: 3.8-4.5 hours (range 3-5 hours) in healthy adults; prolonged in elderly or hepatic/renal impairment. Clinical context: repeated dosing may require extended intervals in renal impairment.
Calcipotriene: 12-24 hours; betamethasone dipropionate: 4-6 hours (parent), 3-5 hours (active metabolite betamethasone 17-propionate).
Acetaminophen: primarily via glucuronidation (UGT1A1, UGT1A6, UGT1A9) and sulfation; minor CYP2E1 oxidation to NAPQI (toxic metabolite). Hydrocodone: CYP3A4 and CYP2D6; N-demethylation to norhydrocodone; O-demethylation to hydromorphone (CYP2D6).
Calcipotriene undergoes hepatic metabolism primarily via cytochrome P450 (CYP) enzymes, including CYP24A1. Betamethasone dipropionate is metabolized in the liver via CYP3A4.
Acetaminophen: primarily renal excretion of conjugated metabolites (glucuronide and sulfate) with approximately 5% excreted unchanged. Hydrocodone: renal excretion as unchanged drug and metabolites (O-demethylated and N-demethylated); total renal excretion accounts for about 60-70% of dose (parent and metabolites). Biliary/fecal elimination is minimal.
Calcipotriene: renal elimination of metabolites; betamethasone dipropionate: primarily renal (70%) and biliary/fecal (30%) as metabolites.
Acetaminophen: 10-25% bound, nonspecific binding to albumin. Hydrocodone: 25-50% bound, primarily to albumin and alpha-1-acid glycoprotein.
Calcipotriene: ~94% bound to plasma proteins; betamethasone dipropionate: ~64% bound (predominantly albumin).
Acetaminophen: 0.8-1.0 L/kg, indicating distribution into total body water; clinically relevant for loading dose calculations. Hydrocodone: 3.0-4.0 L/kg, suggesting extensive tissue distribution; higher Vd may require higher loading doses but has no clinical target.
Calcipotriene: >1 L/kg (extensive tissue distribution); betamethasone dipropionate: not well characterized, likely large due to lipophilicity.
Acetaminophen: oral bioavailability 85-95% (first-pass metabolism minimal). Hydrocodone: oral bioavailability about 25-45% due to first-pass hepatic metabolism; significant interindividual variability.
Topical: minimal systemic absorption (<1% for calcipotriene, ~10-15% for betamethasone dipropionate via inflamed skin).
GFR 10-50 m L/min: administer every 6 hours; GFR <10 m L/min: administer every 8 hours; avoid in severe impairment due to acetaminophen metabolite accumulation.
No specific dose adjustment required for renal impairment. Use with caution in severe renal impairment due to potential for systemic absorption.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50% or extend interval; Child-Pugh C: use with caution, avoid if possible, consider alternative therapy.
No specific dose adjustment required for hepatic impairment. Use with caution in severe hepatic impairment due to potential for systemic corticosteroid effects.
Dosing based on hydrocodone component: 0.1-0.2 mg/kg/dose every 4-6 hours; maximum daily acetaminophen limit: 75 mg/kg/day; not recommended for children <2 years.
Safety and efficacy in children <12 years have not been established. For children ≥12 years, apply once daily to affected areas, limit use to <30 g/week, and avoid prolonged use.
Initiate at lowest effective dose, typically 1 tablet (2.5-5 mg hydrocodone) every 6 hours; monitor for respiratory depression and acetaminophen toxicity; avoid in frail elderly with hepatic impairment.
No specific dose adjustment required, but use with caution due to increased risk of skin atrophy and systemic effects. Avoid prolonged use and apply to limited areas.
Addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion of acetaminophen; neonatal opioid withdrawal syndrome; interaction with alcohol; risk of medication errors.
None.
Hepatotoxicity from acetaminophen overdose; respiratory depression; increased intracranial pressure; CNS depression; elderly/debilitated patients; renal impairment; opioid-induced hyperalgesia; serotonin syndrome; interaction with CNS depressants; risk of adrenal insufficiency; severe hypotension; use in patients with gastrointestinal obstruction; convulsion risk; severe hepatic impairment; urinary retention; acute abdominal conditions; hypothyroidism; prostatic hypertrophy; adrenocortical insufficiency; pregnancy/lactation; pediatric use; geriatric use; renal impairment; hepatic impairment.
Systemic absorption can cause reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, Cushing's syndrome, hyperglycemia, and glucosuria.,Local adverse reactions may include skin atrophy, striae, telangiectasias, burning, pruritus, folliculitis, and allergic contact dermatitis.,May cause hypercalcemia and hypercalciuria due to calcipotriene component; monitor serum and urine calcium levels in patients with renal impairment or high doses.,Avoid use on face, groin, axillae, or intertriginous areas due to increased risk of adverse effects.,Not recommended for long-term continuous use due to potential for skin atrophy and systemic effects.
Hypersensitivity to acetaminophen or hydrocodone; significant respiratory depression; acute or severe bronchial asthma; upper airway obstruction; known or suspected gastrointestinal obstruction; paralytic ileus; concomitant use of monoamine oxidase inhibitors (MAOIs) or within 14 days; severe hepatic impairment (acetaminophen toxicity risk); acute alcoholism.
Hypersensitivity to calcipotriene, betamethasone dipropionate, or any component of the formulation.,Patients with known calcium metabolism disorders (e.g., hypercalcemia, vitamin D toxicity).,Patients with known or suspected skin infections, including viral (e.g., herpes simplex, varicella), fungal, or bacterial infections.,Use on eroded, ulcerated, or exudative skin.
Avoid alcohol consumption during therapy; ethanol increases acetaminophen hepatotoxicity risk and enhances CNS depression. Grapefruit juice may inhibit CYP2D6 (minor effect) but no significant clinical interaction. No other specific food restrictions.
No significant food interactions. No dietary restrictions necessary for this topical medication.
First trimester: Acetaminophen considered low risk; hydrocodone is a pregnancy category C drug. Data from retrospective studies suggest a small increased risk of certain congenital malformations (e.g., neural tube defects, cleft palate) with first trimester opioid use, but absolute risk is low. Second trimester: Low risk as above. Third trimester: Prolonged use of hydrocodone can cause neonatal opioid withdrawal syndrome (NOWS); acetaminophen is safe. Use only if benefit outweighs risk.
Topical calcipotriene/betamethasone dipropionate has low systemic absorption; however, betamethasone is a corticosteroid. Animal studies with high-dose topical corticosteroids show increased risk of cleft palate and fetal growth restriction. In humans, first-trimester use of potent corticosteroids is associated with a small increased risk of oral clefts (OR 1.5). Second/third trimester: Prolonged use may cause fetal adrenal suppression and low birth weight. Avoid application to large areas (>30% BSA) or under occlusion.
Acetaminophen excretion in breast milk is low (M/P ratio ~0.9). Hydrocodone is excreted in small amounts (M/P ratio ~2.1). The relative infant dose is estimated to be 2.5-3.5% of maternal weight-adjusted dose for hydrocodone. Monitor infant for sedation and respiratory depression. Consider benefit to mother and potential neonatal opioid withdrawal if used chronically.
Minimal systemic absorption after topical use. No specific M/P ratio available. Exercise caution: avoid application to breast area to prevent infant ingestion. Monitor infant for signs of adrenal suppression (rare). Use lowest effective dose for shortest duration.
During pregnancy, increased plasma volume and enhanced hepatic clearance may reduce serum concentrations of both drugs. However, dosing adjustments are not routinely recommended due to risk of undertreatment. Use the lowest effective dose of hydrocodone for the shortest duration. For acetaminophen, maximum daily dose should not exceed 3000 mg to avoid hepatotoxicity.
No dose adjustment needed for topical use. However, restrict application to <30% body surface area and avoid prolonged treatment; use shortest possible duration. Systemic absorption may increase with psoriatic skin barrier disruption; monitor for corticosteroid side effects.
Acetaminophen-hydrocodone is contraindicated in severe respiratory depression, acute or severe bronchial asthma, and known hypersensitivity. Monitor for respiratory depression, especially in elderly or debilitated patients. Avoid use with other acetaminophen-containing products to prevent hepatotoxicity. Hydrocodone is a prodrug metabolized by CYP2D6 to hydromorphone; CYP2D6 ultrarapid metabolizers may experience toxicity. Use with caution in patients with head injury, increased intracranial pressure, or severe hepatic impairment. Naloxone is the reversal agent for opioid effects; acetylcysteine for acetaminophen overdose.
Apply only to psoriatic plaques, not to normal skin or flexures. Maximum weekly dose: 100g. Avoid occlusion. Use with caution on face, genitals, and intertriginous areas due to risk of corticosteroid atrophy. Discontinue if hypersensitivity develops. Monitor for hypercalcemia if used on extensive areas. Not recommended for use in children under 18 years.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Avoid alcohol and other CNS depressants (e.g., benzodiazepines, sedatives) as they increase risk of severe drowsiness and respiratory depression.,Do not exceed 4000 mg of acetaminophen per day from all sources; check labels of other medications.,This medication may cause dizziness or drowsiness; avoid driving or operating heavy machinery until you know how it affects you.,Store securely out of reach of others, especially children, as misuse can cause overdose and death.,Do not stop abruptly; withdrawal may occur. Taper under medical supervision.,Contact emergency if you experience trouble breathing, extreme drowsiness, or signs of allergic reaction.,Report any history of substance abuse, as this medication has abuse potential.
For external use only.,Apply once daily to psoriatic lesions only, avoiding unaffected skin.,Do not use more than 100 grams per week.,Do not cover with bandages or tight dressings.,Wash hands after application unless treating hands.,Avoid contact with eyes, mouth, and mucous membranes.,Do not use on face, armpits, or groin unless directed.,Inform your healthcare professional if you experience burning, itching, or skin thinning.,Use only on children under 18 if specifically prescribed.,Do not use for more than 4 weeks without medical evaluation.
"Hydrocodone, an opioid agonist, and scopolamine, an anticholinergic agent, both exhibit central nervous system (CNS) depressant effects. When co-administered, their combined activity can lead to additive CNS depression, resulting in enhanced sedation, respiratory depression, and cognitive impairment. This interaction may also increase the risk of constipation and urinary retention due to additive anticholinergic effects from both drugs."
"Pargyline, a monoamine oxidase inhibitor (MAOI), irreversibly inhibits the metabolism of amines, leading to increased intraneuronal stores of norepinephrine. Hydrocodone, a semisynthetic opioid, can release these stored catecholamines, potentially causing a hypertensive crisis, serotonin syndrome, or CNS excitation. Coadministration may also result in excessive sedation and respiratory depression due to additive CNS depressant effects, requiring immediate clinical attention."
"Hydrocodone, an opioid agonist, and oxprenolol, a non-selective beta-adrenoceptor antagonist, are both central nervous system (CNS) depressants. Their combined use can lead to additive CNS depression, resulting in excessive sedation, respiratory depression, hypotension, and bradycardia. This interaction is particularly dangerous in patients with compromised cardiac or respiratory function, potentially leading to coma or death."
"Coadministration of Betamethasone, a potent corticosteroid, may reduce the therapeutic efficacy of Miglustat, a glucosylceramide synthase inhibitor used for Gaucher disease and Niemann-Pick type C. Betamethasone can induce hepatic CYP3A4 isoenzymes, potentially increasing the metabolism of Miglustat, though Miglustat is primarily renally excreted and not extensively metabolized. The interaction may also involve corticosteroid-mediated alterations in drug transport or GlcCer synthesis pathways, leading to decreased Miglustat plasma concentrations and diminished clinical response, including worsening of neurological symptoms in Niemann-Pick disease."
"Concomitant use of betamethasone, a corticosteroid, with donepezil, a cholinesterase inhibitor used in Alzheimer's disease, may increase the risk of gastrointestinal adverse effects including gastric ulceration and hemorrhage. Corticosteroids inhibit prostaglandin synthesis and mucosal protection, while donepezil enhances cholinergic tone, increasing gastric acid secretion. This additive effect on the gastric mucosa can lead to clinically significant ulcer formation or gastrointestinal bleeding, particularly in elderly patients."
"Betamethasone, a potent corticosteroid, can induce hyperglycemia and dyslipidemia, potentially counteracting the lipid-lowering effects of atorvastatin. Concurrent use may increase the risk of corticosteroid-related adverse effects such as fluid retention, hyperglycemia, and myopathy. Atorvastatin may also increase systemic exposure to corticosteroids via inhibition of CYP3A4, though this interaction is generally not clinically significant."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ACETAMINOPHEN AND HYDROCODONE BITARTRATE vs CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE, answered by our medical review team.
ACETAMINOPHEN AND HYDROCODONE BITARTRATE is a Opioid Agonist that works by Acetaminophen: analgesic and antipyretic effects via inhibition of cyclooxygenase (COX) and activation of descending serotonergic pathways; central action. Hydrocodone: mu-opioid receptor agonist; activates G-protein coupled receptors to modulate pain perception and emotional response.. CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE is a Vitamin D Analog that works by Calcipotriene is a synthetic vitamin D3 analog that binds to vitamin D receptors, regulating cell proliferation and differentiation. Betamethasone dipropionate is a corticosteroid that reduces inflammation by inducing phospholipase A2 inhibitory proteins (lipocortins), inhibiting arachidonic acid release, and decreasing prostaglandin and leukotriene synthesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ACETAMINOPHEN AND HYDROCODONE BITARTRATE and CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ACETAMINOPHEN AND HYDROCODONE BITARTRATE is: 1-2 tablets (containing 5-10 mg hydrocodone and 300-325 mg acetaminophen) orally every 4-6 hours as needed for pain; maximum 8 tablets per day.. The standard adult dose of CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE is: Apply once daily to affected areas of skin, not exceeding 100 g/week or 30 m L/day. Do not use under occlusive dressings.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ACETAMINOPHEN AND HYDROCODONE BITARTRATE and CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ACETAMINOPHEN AND HYDROCODONE BITARTRATE is classified as Category D/X. First trimester: Acetaminophen considered low risk; hydrocodone is a pregnancy category C drug. Data from retrospective studies suggest a small increased risk of certain congenital. CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE is classified as Category C. Topical calcipotriene/betamethasone dipropionate has low systemic absorption; however, betamethasone is a corticosteroid. Animal studies with high-dose topical corticosteroids show. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.